SEC14L4: A Potential Drug Target and Biomarker (G284904)

Target Name: SEC14L4

NCBI ID: G284904

SEC14L4

SEC14L4: A Potential Drug Target and Biomarker

Spermidine-modified RNA (SMRNA) is a ubiquitous molecule that plays a critical role in cellular signaling and gene regulation. One of the well-known SMRNA molecules is SEC14L4, which is a potential drug target and biomarker. SEC14L4 is a 21-kDa RNA molecule that is expressed in various cell types, including muscle, liver, and pancreas. It is highly conserved across different species, and its structure consists of a single exon and a spliced 鈥嬧?媏xon that is joined to the 5' end of a longer transcript.

SEC14L4 is a key regulator of gene expression and has been involved in various cellular processes, including cell growth, apoptosis, and inflammation. It is a potent inhibitor of the protein kinase Akt (AKT), which is a key regulator of cell survival and growth . In addition, SEC14L4 has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion.

The potential drug target for SEC14L4 is the Akt pathway, which is a widely-studied signaling pathway that is involved in various cellular processes, including cell survival, growth, and angiogenesis. Activation of the Akt pathway has been implicated in the development and progression of many diseases, including cancer, diabetes, and neurodegenerative disorders. Therefore, targeting SEC14L4 and its downstream effects may be a promising strategy for the development of new therapeutic approaches.

SEC14L4 has also been shown to be a potential biomarker for several diseases, including cancer, diabetes, and neurodegenerative disorders. The expression of SEC14L4 has been observed in various disease tissues and has been associated with the development and progression of these diseases. For example, studies have shown that SEC14L4 is overexpressed in various cancer tissues and is associated with poor prognosis. Similarly, SEC14L4 has been shown to be overexpressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder.

In addition to its potential drug and biomarker applications, SEC14L4 also has interesting structural and functional characteristics that may be relevant to its study. The single exon and spliced 鈥嬧?媏xon structure of SEC14L4 is unique and is conserved across different species. This suggests that SEC14L4 has a critical role in regulating gene expression and has implications for its study as a drug target or biomarker.

The function of SEC14L4 is also related to its structural characteristics. The 5' end of SEC14L4 is rich in conserved secondary structure, including a GCCA sequence and a GGAA consensus sequence. These sequences are commonly found in RNA structures that are involved in protein structures -RNA interactions, including RNA-protein binding and RNA-DNA binding. Therefore, the structural features of SEC14L4 may be relevant to its function in regulating gene expression and cell signaling.

In conclusion, SEC14L4 is a promising drug target and biomarker that has unique structural and functional characteristics. Its conserved 5' end structure and its involvement in the Akt pathway make it a potential target for small molecules or antibodies that can modulate its activity. Further studies are needed to fully understand the role of SEC14L4 in cellular signaling and its potential as a drug or biomarker.

Protein Name: SEC14 Like Lipid Binding 4

Functions: Probable hydrophobic ligand-binding protein; may play a role in the transport of hydrophobic ligands like tocopherol, squalene and phospholipids

The "SEC14L4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC14L4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets